ABUS
Arbutus Biopharma Corporation Common Stock
stockNASDAQ
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.88 | 2026-11-03 | -1.29% | 1.939 |
| 1M | 4.22 | 2026-10-09 | -9.24% | 1.566 |
| 3M | 4.59 | 2026-08-10 | -16.56% | 1.312 |
| 6M | 4.39 | 2026-05-11 | -12.76% | 1.111 |
| 1Y | 4.59 | 2025-11-10 | -16.56% | 1.252 |
| 2Y | 3.73 | 2024-11-11 | +2.68% | — |
| 5Y | 3.48 | 2021-11-10 | +10.06% | 0.969 |
Arbutus Biopharma Corporation Common Stock (NASDAQ:ABUS) stock price today is $3.83, and today's volume is 1,077,488. ABUS is up 2.957% today. The 30 day average volume is 4.63M. ABUS market cap is $758.74M with 198.11M shares outstanding.